YAP1 and rhabdomyosarcoma: However, as recently reported for rhabdomyosarcoma [46], it is possible that dasatinib might not be sufficient to phenocopy the effects of RASSF1A, and that the combination of dasatinib with RASSF1A-activating drugs such as DNMTi is needed to suppress YAP1 activity and YAP1-mediated FOXM1 and ERα expression.